Study of INV-202 in Patients With Obesity and Metabolic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

June 13, 2024

Study Completion Date

February 14, 2025

Conditions
ObesityMetabolic Syndrome
Interventions
DRUG

INV-202

tablet, once daily, oral

DRUG

Placebo

tablet, once daily, oral

Trial Locations (24)

V3L 3W5

Office of David H. Shu, MD, New Westminster

B4N 3R7

Centricity Research -New Minas, New Minas

L6T 0G1

Aggarwal and Associates, Limited, Brampton

L8L 5G8

Wharton Medical Clinic (WMC) - Toronto, Hamilton

N5W 6A2

Milestone Research Inc, London

Diex Recherche Trois-Rivieres, Trois-Rivières

L1J 2K9

Centricity Research - Oshawa, Oshawa

N7T 4X3

Bluewater Clinical Research Group Inc, Sarnia

M3J 0K2

Canadian Phase Onward Inc., Toronto

M9V 4B4

Dr. Anil K. Gupta Medicine Professional Corporation, Toronto

N2J 1C4

Dr. Sameh Fikry Medicine Professional Corporation, Waterloo

N2T 0C1

Clinical Research Solutions, Waterloo

G7H 7K9

Ecogene-21, Chicoutimi

J6E 2B4

DIEX Research Joliette, Joliette

G6W OM5

Centricity Research - Levis, Lévis

J7J 2K8

Centricity Research - Mirabel, Mirabel

H4N 2W2

9109-0126 Quebec Inc, Montreal

H9R 4S3

Centricity Research - Pointe-Claire, Pointe-Claire

G1N 4V3

DIEX Research Quebec, Québec

G1V 4W2

Centre des maladies lipidique deq Quebec, CMLQ Inc., Québec

G2J 0C4

Alpha Recherche Clinique - Lebourgneuf, Québec

G3K 2P8

Alpha Recherche Clinique Val-Bélair, Québec

J1L 0H8

Diex Recherche Sherbrooke, Sherbrooke

G6P 6P6

Diex Recherche Victoriaville, Victoriaville

Sponsors
All Listed Sponsors
lead

Inversago Pharma Inc.

INDUSTRY

NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome | Biotech Hunter | Biotech Hunter